CNTA News and Press, Centessa Pharmaceuticals plc From 11/30/22

BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer. In ...

Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q3 GAAP EPS of -$0.57. Cash and Cash Equivalents: $444.8 million as of September 30, 2022, Research & Development Expenses: $36.7 million for the quarter ended September 30, 2022, compared to $25.9 million fo...

– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 o bservation study on track to begin this quarter – – Data readout of SerpinPC Phase 2...

BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC for the treatme...

BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will particip...

For the first time since Oct. 13, Centessa Pharmaceuticals ( NASDAQ: CNTA ) is showing gains. In Thursday afternoon trading, the biotech is up 10% . There is no news or other catalysts that might explain the jump. However, based on a technical analysis, Centess...

New York, New York--(Newsfile Corp. - October 13, 2022) - Levi & Korsinsky, LLP notifies investors in Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ: CNTA) of a class action securities lawsuit. The lawsuit on behalf of Centessa investors has been commenced in the the...

NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Centessa Pharmaceuticals plc. ("Centessa" or the "Company") (NASDAQ:CNTA) and reminds investors of the November 28, 2022 deadline to seek ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Centessa To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 30, 2022) - Faruqi & Faruqi, LLP, a leading national securities law fi...

– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE)...